Dermatomyositis Clinical Trial
Official title:
Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis
Juvenile dermatomyositis (JDM) is a connective tissue disease that causes skin rash and weak muscles in children. The purpose of this study is to measure the absorption of oral prednisolone and intravenous (IV) methylprednisolone and to determine levels of disease activity indicators in the blood. These levels will be compared to see if there are patterns specific to active and less active JDM.
JDM is a connective tissue disease that is characterized by inflammation of the muscles and
the skin. Corticosteroids, such as prednisolone and methylprednisolone, can be administered
to help control symptoms of the disease, but absorption patterns of these medications in
oral and IV forms are unknown. This study will assess absorption of oral prednisolone and IV
methylprednisolone, measure levels of two disease activity indicators (von Willebrand factor
and neopterin), and correlate these values in children with JDM.
Patients will participate in this study twice within a period of up to a year, once when the
patient's disease is active, and again 6 to 12 months later when the disease is less active.
Each of the two study periods will last two nights and two days. Patients will be admitted
to the hospital the first night, and a small IV port will be inserted in the patient's arm
the first morning to allow for multiple blood draws without additional needle sticks.
Patients will receive oral prednisolone the first morning and IV methylprednisolone the
second morning. Baseline blood draws will be performed prior to administration of drug, with
13 additional draws over a 6 hour period following drug administration. Following the final
blood draw on the second day, the IV port will be removed from the patient's arm and the
patient will be discharged from the hospital.
Blood drawn from patients will be assessed for absorption of the drugs and levels of von
Willebrand factor and neopterin. Patients will undergo the same sequence of events sometime
between 6 to 12 months after the first hospitalization, after their vasculitis is judged to
be less active.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A | |
Recruiting |
NCT06462768 -
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
|